Analysis of the influence of five variables on an established immunoaffinity chromatography procedure to purify a picchia pastoris yeast derived-HBsAg for pharmaceutical use

Immunoaffinity chromatography (IAC) has a wide application in protein purification. The aim of the study was to investigate the influence of five operational factors on an IAC procedure to purify a yeast derived-Hepatitis B surface antigen (rHBsAg) for pharmaceutical use. The immunosorbent adsorptio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Valdes, Rodolfo, Medina, Yenisley, Fernández, Eutimio G., Geada, Déborah, Ferro, Williams, Álvarez, Tatiana, Padilla, Sigifredo, Guevara, Yaryse, Tamayo, Andrés, Gomez, Leonardo, Montero, José, Figueroa, Alejandro, Calas, Gisela, García A., Cristina
Formato: Articulo
Lenguaje:Inglés
Publicado: 2008
Materias:
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/7705
http://www.latamjpharm.org/trabajos/27/6/LAJOP_27_6_1_12_LD68X28956.pdf
Aporte de:
Descripción
Sumario:Immunoaffinity chromatography (IAC) has a wide application in protein purification. The aim of the study was to investigate the influence of five operational factors on an IAC procedure to purify a yeast derived-Hepatitis B surface antigen (rHBsAg) for pharmaceutical use. The immunosorbent adsorption capacity of the rHBsAg is affected at 4 °C. The applied antigen concentration, 100-1000 μg mL<sup>-1</sup>, does not have influence on this IAC efficiency. The residence time, applied antigen amount and column geometry have a significant influence on the adsorption and elution capacity, and recovery of the rHBsAg. There is a marked retention of the rHBsAg into the matrix, which is reduced at residence times higher than 2 h. A high height/diameter ratio of the column, 3.75, reduces the antigen adsorption to the matrix but increases the recovery and the productivity for this high molecular weight (multiple chemical forms) antigen and a high affinity constant ligand. The solution of the rHBsAg retention into the matrix could increase by 30% the active pharmaceutical ingredient purification and the Hepatitis B vaccine production.